Astrazeneca ADR diskutieren

+++ 08:14 Großbritannien lässt Astrazeneca-Impfstoff zu +++
Die britische Arzneimittelbehörde MHRA lässt den Corona-Impfstoff des schwedisch-britischen Pharmakonzerns Astrazeneca für Großbritannien zu. Es handelt sich um eine Notfallzulassung. Das Vakzin des Unternehmens sowie der Universität Oxford ist kein neuartiger mRNA-Impfstoff wie jene von Biontech/Pfizer oder Moderna, sondern ein herkömmlicher Vektorimpfstoff, der allerdings wesentlich günstiger ist.

Nach dem jetzt freigegebenen Mittel von AstraZeneca warten laut Regierung noch mindestens drei weitere auf ihre Zulassung, darunter auch das russische Vakzin Sputnik V. Biontech und Pfizer sollen für ihr Serum inzwischen auch eine Notfallzulassung beantragt haben. Informationsminister Prakash Javadeka sagte, sein Land sei möglicherweise das einzige, in dem bald bis zu vier Impfstoffe zum Einsatz kommen können.

Highlights of Total Revenue in the year included:

• An increase in Product Sales of 10% (11% at CER) to $25,890m. The quarter was the first for many years with Product Sales in excess of $7,000m. New-medicine Total Revenue improved by 33% in the year to $13,950m, including growth in Emerging Markets of 53% (59% at CER) to $2,845m. Globally, the new medicines represented 52% of Total Revenue (FY 2019: 43%)
• Oncology growth of 23% (24% at CER) to $11,455m, while New CVRM7 increased by 7% (9% at CER) to $4,702m. Respiratory & Immunology declined by 1% (stable at CER) to $5,375m, a reflection of the impact in China of COVID-19
• An increase in Emerging Markets of 7% (10% at CER) to $8,711m, with China growth of 10% (11% at CER) to $5,375m. In the US, Total Revenue increased by 13% to $8,833m and in Europe by 10% (9% at CER) to $5,540m. Both regions delivered stronger growth rates in the final quarter compared to the full year – see the Regional Total Revenue section for details
• Reported EPS of $2.44 in the year represented an increase of 137% (142% at CER). Core EPS grew by 15% (18% at CER) to $4.02

Guidance
The Company provides guidance for FY 2021 at CER.
Total Revenue is expected to increase by a low-teens percentage, accompanied by faster growth in Core EPS to $4.75 to $5.00.
The guidance does not incorporate any revenue or profit impact from sales of COVID-19 Vaccine AstraZeneca (C19VAZ). The Company intends to report these sales separately from the next quarter. Similarly, the guidance excludes the proposed acquisition by the Company of Alexion Pharmaceuticals, Inc. (Alexion), anticipated to close in Q3 2021. AstraZeneca recognises the heightened risks and uncertainties from the impact of COVID-19. Variations in performance between quarters can be expected to continue.

Highlights of Total Revenue in the quarter included:

• An increase in Product Sales of 15% (11% at CER) to $7,257m. New medicines7 Total Revenue improved by 30% (26% at CER) in the quarter to $3,891m, including growth in Emerging Markets of 33% (30% at CER) to $874m. Globally, new medicines represented 53% of Total Revenue (Q1 2020: 47%). Q1 2020 benefitted from a low-to-mid single-digit percentage increase in sales following short-term inventory increases in the distribution channel, an indirect effect of the COVID-19 pandemic
• Oncology growth of 20% (16% at CER) to $3,024m, an increase in New CVRM8 of 19% (15% at CER) to $1,306m. Respiratory & Immunology (R&I), however, declined by 1% (4% at CER) to $1,546m, predominately reflecting the impact of stocking of an authorised generic version of Symbicort in the US during Q1 2020 and phasing of COVID-19 impacts
• An increase in Emerging Markets of 14% (10% at CER) to $2,592m, with China growth of 19% (10% at CER) to $1,679m. In the US, Total Revenue increased by 10% to $2,310m and in Europe by 28% (18% at CER) to $1,546m